Absci Corporation
NASDAQ:ABSIBiotechnology
+$0.08 today
- Market cap
- $1.41B
- Beta
- 2.46
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$0.77
Volume 5.66M
Average 5.10M
ABSI Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Absci CorporationNASDAQ: ABSI
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $19.28M rose 17.8% year over year, behind the +24.0% change in trailing-twelve-month research & development. Sequentially, it fell 24.0% from the prior quarter. Over 3 fiscal years it compounded at +11.4% a year.
Context
- Research & development amounted to 2907.8% of revenue in FY2025, up 1499.3 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +17.8% toward the trailing-twelve-month pace of +24.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 81.42M USD
- Year-over-year change
- +27.5%
- 4-year CAGR
- +16.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.42M | +27.5% |
| FY2024 | 2024-12-31 | 63.86M | +32.9% |
| FY2023 | 2023-12-31 | 48.07M | -18.4% |
| FY2022 | 2022-12-31 | 58.91M | +32.1% |
| FY2021 | 2021-12-31 | 44.59M | — |
Research & Development vs competitors
How ABSI compares with its peers on the latest reported figures
- ABSI's LTM Mar 2026 research & development of $84.33M is the lowest of the 3 companies compared; the peer median is $205.49M.
- Its year-over-year change of +24.0% is the 2nd highest of 3, against a peer median of +15.0%.
- Research & development amounts to 4593.1% of revenue for ABSI, versus a peer median of 489.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
GENBGenerate Biomedicines, Inc. | FY2025 | $224.7M | +28.2% | — | 704.5% |
| LTM Sep 2026 | $186.28M | +1.9% | +20.1% | 274.5% | |
| LTM Mar 2026 | $84.33M | +24.0% | +11.4% | 4593.1% | |
| Peer median (excluding ABSI) | $205.49M | +15.0% | +20.1% | 489.5% | |
Competitors are the stored peer set for ABSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.78M | 5.75M | 5.72M | 4.53M | 2.8M |
| Cost of Revenue | 44.59M | 58.91M | 47.57M | 62.46M | 11.74M |
| Gross Profit | (39.8M) | (53.16M) | (41.85M) | (57.93M) | (8.94M) |
| Gross Margin | -832.4% | -925.0% | -731.9% | -1277.6% | -319.4% |
| Research & Development | 44.59M | 58.91M | 48.07M | 63.86M | 81.42M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 35.06M |
| Operating Expenses | 35.43M | 53.59M | 73.67M | 50.96M | 115.78M |
| Depreciation & Amortization | 6.65M | 13.04M | 14M | 13.39M | 11.74M |
| EBITDA | (67.68M) | (91.36M) | (79.68M) | (94.1M) | (103.16M) |
| EBITDA Margin | -1415.4% | -1589.6% | -1393.5% | -2075.4% | -3684.4% |
| Operating Income | (75.24M) | (106.75M) | (115.52M) | (108.89M) | (124.72M) |
| Operating Margin | -1573.4% | -1857.5% | -2020.2% | -2401.6% | -4454.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.43M | 972K | 1.01M | 565K | 209K |
| Other Income / Expenses | (34.62M) | 1.39M | 5.05M | 5.85M | 9.6M |
| Income Before Tax | (109.86M) | (105.37M) | (110.47M) | (103.04M) | (115.11M) |
| Pre-Tax Margin | -2297.3% | -1833.4% | -1931.9% | -2272.5% | -4111.2% |
| Income Tax Expense | (8.9M) | (461K) | 100K | 70K | 69K |
| Net Income | (100.96M) | (104.9M) | (110.57M) | (103.11M) | (115.18M) |
| Net Margin | -2111.3% | -1825.4% | -1933.6% | -2274.1% | -4113.7% |
| EPS (Basic) | (1.11) | (1.15) | (1.20) | (0.94) | (0.84) |
| EPS (Diluted) | (1.11) | (1.15) | (1.20) | (0.94) | (0.84) |
| Weighted Avg Shares | 92.65M | 90.85M | 92.03M | 110.24M | 136.78M |
| Weighted Avg Shares (Diluted) | 92.65M | 90.85M | 92.03M | 110.24M | 136.78M |
Absci Corporation
NASDAQ:ABSI
Intrinsic Alpha fair value
Locked
Current Price
$8.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.